Clinical Research Directory
Browse clinical research sites, groups, and studies.
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Sponsor: Emory University
Summary
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Official title: Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2023-11-09
Completion Date
2027-06-30
Last Updated
2025-09-11
Healthy Volunteers
No
Interventions
Atovaquone
Given PO
Biopsy
Undergo biopsy
Computed Tomography
Undergo CT
Paracentesis
Undergo paracentesis
Locations (1)
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States